JPMorgan raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $115 from $95 and keeps an Overweight rating on the shares. The firm remains bullish on the company’s Cortrophin Gel, which it views as a “highly-durable” growth driver for ANI.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright
- ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim
- ANI Pharmaceuticals Highlights Commercialization Focus Amid Challenges
- ANI Pharmaceuticals’ Record Earnings and Optimistic Outlook
- ANI Pharmaceuticals price target raised to $77 from $65 at Truist